scholarly journals Taking in the trash: bioreactors for the mass production of clinical-grade extracellular vesicles

2022 ◽  
Author(s):  
Matthew J. Robeson ◽  
Michael E. Davis
Keyword(s):  
Extracellular Vesicles ◽  
Mass Production ◽  
Clinical Grade

scholarly journals Emerging biogenesis technologies of extracellular vesicles for tissue regenerative therapeutics

2021 ◽  
Vol 12 ◽  
pp. 204173142110190
Author(s):  
Jung-Hwan Lee ◽  
Ji-Young Yoon ◽  
Jun Hee Lee ◽  
Hae-Hyoung Lee ◽  
Jonathan C Knowles ◽  
...  
Keyword(s):  
Extracellular Vesicles ◽  
Chemical Treatment ◽  
Mass Production ◽  
Disease Status ◽  
Clinical Translation ◽  
Technological Advances ◽  
Tissue Healing ◽  
Bio Imaging ◽  
Key Issues ◽  
Treatment Application

Extracellular vesicles (EVs), including exosomes, carry the genetic packages of RNA, DNA, and proteins and are heavily involved in cell-cell communications and intracellular signalings. Therefore, EVs are spotlighted as therapeutic mediators for the treatment of injured and dysfunctional tissues as well as biomarkers for the detection of disease status and progress. Several key issues in EVs, including payload content and bioactivity, targeting and bio-imaging ability, and mass-production, need to be improved to enable effective therapeutics and clinical translation. For this, significant efforts have been made recently, including genetic modification, biomolecular and chemical treatment, application of physical/mechanical cues, and 3D cultures. Here we communicate those recent technological advances made mainly in the biogenesis process of EVs or at post-collection stages, which ultimately aimed to improve the therapeutic efficacy in tissue healing and disease curing and the possibility of clinical translation. This communication will help tissue engineers and biomaterial scientists design and produce EVs optimally for tissue regenerative therapeutics.

scholarly journals Methodologies to Isolate and Purify Clinical Grade Extracellular Vesicles for Medical Applications

Cells ◽  
2022 ◽  
Vol 11 (2) ◽  
pp. 186
Author(s):  
Asma Akbar ◽  
Farzaneh Malekian ◽  
Neda Baghban ◽  
Sai Priyanka Kodam ◽  
Mujib Ullah
Keyword(s):  
Drug Delivery ◽  
Extracellular Vesicles ◽  
Medical Applications ◽  
Clinical Use ◽  
Clinical Grade ◽  
Isolation And Purification ◽  
The Past ◽  
Therapeutic Benefits ◽  
Nano Drug Delivery ◽  
Purification Methods

The use of extracellular vesicles (EV) in nano drug delivery has been demonstrated in many previous studies. In this study, we discuss the sources of extracellular vesicles, including plant, salivary and urinary sources which are easily available but less sought after compared with blood and tissue. Extensive research in the past decade has established that the breadth of EV applications is wide. However, the efforts on standardizing the isolation and purification methods have not brought us to a point that can match the potential of extracellular vesicles for clinical use. The standardization can open doors for many researchers and clinicians alike to experiment with the proposed clinical uses with lesser concerns regarding untraceable side effects. It can make it easier to identify the mechanism of therapeutic benefits and to track the mechanism of any unforeseen effects observed.

scholarly journals Intratracheal administration of clinical-grade mesenchymal stem cell-derived extracellular vesicles reduces lung injury in a rat model of bronchopulmonary dysplasia

2019 ◽  
Vol 316 (1) ◽  
pp. L6-L19 ◽  
Author(s):  
Andrea Porzionato ◽  
Patrizia Zaramella ◽  
Arben Dedja ◽  
Diego Guidolin ◽  
Kelly Van Wemmel ◽  
...  
Keyword(s):  
Extracellular Vesicles ◽  
Bronchopulmonary Dysplasia ◽  
Rat Model ◽  
Ambient Air ◽  
Total Surface Area ◽  
Physiological Solution ◽  
Protective Effects ◽  
Clinical Grade ◽  
Alveolar Volume ◽  
Intratracheal Administration

Mesenchymal stem cells (MSCs) prevent the onset of bronchopulmonary dysplasia (BPD) in animal models, an effect that seems to be mediated by their secreted extracellular vesicles (EVs). The aim of this study was to compare the protective effects of intratracheally (IT) administered MSCs versus MSC-EVs in a hyperoxia-induced rat model of BPD. At birth, rats were distributed as follows: animals raised in ambient air for 2 wk ( n = 10), and animals exposed to 60% oxygen for 2 wk and treated with IT-administered physiological solution ( n = 10), MSCs ( n = 10), or MSC-EVs ( n = 10) on postnatal days 3, 7, and 10. The sham-treated hyperoxia-exposed animals showed reductions in total surface area of alveolar air spaces, and total number of alveoli ( Nalv), and an increased mean alveolar volume (Valv). EVs prompted a significant increase in Nalv ( P < 0.01) and a significant decrease in Valv ( P < 0.05) compared with sham-treated animals, whereas MSCs only significantly improved Nalv ( P < 0.05). Small pulmonary vessels of the sham-treated hyperoxia-exposed rats also showed an increase in medial thickness, which only EVs succeeded in preventing significantly ( P < 0.05). In conclusion, both EVs and MSCs reduce hyperoxia-induced damage, with EVs obtaining better results in terms of alveolarization and lung vascularization parameters. This suggests that IT-administered EVs could be an effective approach to BPD treatment.

scholarly journals Clinical-grade cryopreserved doxorubicin-loaded platelets: role of cancer cells and platelet extracellular vesicles activation loop

2020 ◽  
Vol 27 (1) ◽  
Author(s):  
Yu-Wen Wu ◽  
Cheng-Chain Huang ◽  
Chun Austin Changou ◽  
Long-Sheng Lu ◽  
Hadi Goubran ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Extracellular Vesicles ◽  
Activation Loop ◽  
Clinical Grade

scholarly journals Technological advances towards extracellular vesicles mass production

2021 ◽  
pp. 113843
Author(s):  
Alice Grangier ◽  
Julien Branchu ◽  
Jeanne Volatron ◽  
Max Piffoux ◽  
Florence Gazeau ◽  
...  
Keyword(s):  
Extracellular Vesicles ◽  
Mass Production ◽  
Technological Advances

Stroma-free mass production of clinical-grade red blood cells (RBCs) by using poloxamer 188 as an RBC survival enhancer

Transfusion ◽  
2009 ◽  
Vol 49 (11) ◽  
pp. 2285-2295 ◽  
Author(s):  
Eun Jung Baek ◽  
Han-Soo Kim ◽  
Ju-Hye Kim ◽  
Nahn Ju Kim ◽  
Hyun Ok Kim
Keyword(s):  
Red Blood Cells ◽  
Mass Production ◽  
Blood Cells ◽  
Clinical Grade ◽  
Poloxamer 188

scholarly journals Preclinical efficacy and clinical safety of clinical‐grade nebulized allogenic adipose mesenchymal stromal cells‐derived extracellular vesicles

2021 ◽  
Vol 10 (10) ◽  
Author(s):  
Meng‐meng Shi ◽  
Qing‐yuan Yang ◽  
Antoine Monsel ◽  
Jia‐yang Yan ◽  
Cheng‐xiang Dai ◽  
...  
Keyword(s):  
Extracellular Vesicles ◽  
Mesenchymal Stromal Cells ◽  
Stromal Cells ◽  
Clinical Grade ◽  
Clinical Safety ◽  
Preclinical Efficacy

Energy, transport, and consumption in the Industrial Revolution

2019 ◽  
Vol 42 ◽  
Author(s):  
Joseph A. Tainter ◽  
Temis G. Taylor
Keyword(s):  
Mass Production ◽  
Industrial Revolution ◽  
Energy Transport ◽  
Underlying Assumption

Abstract We question Baumard's underlying assumption that humans have a propensity to innovate. Affordable transportation and energy underpinned the Industrial Revolution, making mass production/consumption possible. Although we cannot accept Baumard's thesis on the Industrial Revolution, it may help explain why complexity and innovation increase rapidly in the context of abundant energy.

Sign in / Sign up

Export Citation Format

Share Document